600664.SS
600664.SS
CNE0000009T3
HARBIN PHARMACEUTICAL GROUP CO
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 90/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±39.4% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.1x).

Beta (Market Relation)
0.06x
Defensive
Volatility (5Y p.a.)
39.4% p.a.
5-Year Horizon
Max Drawdown (5Y)
-38.0%
5-Year Horizon
Sharpe Ratio
0.35
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +105.3%
3 Years 43.9% -38.0% 0.62 +29.7%
5 Years 39.4% -38.0% 0.35 +15.9%
10 Years 38.0% -75.2% -0.13 -2.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (43.9%) is noticeably higher than the 5Y average (39.4%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (39.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -75.2% in the extended horizon.
ende